Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Lorazepam
Drug ID BADD_D01318
Description Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic.[A957] It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.[L5095]
Indications and Usage Lorazepam is FDA-approved for the short-term relief of anxiety symptoms related to anxiety disorders and anxiety associated with depressive symptoms such as anxiety-associated insomnia. It is as well used as an anesthesia premedication in adults to relieve anxiety or to produce sedation/amnesia and for the treatment of status epilepticus.[T385] Some off-label indications of lorazepam include rapid tranquilization of an agitated patient, alcohol withdrawal delirium, alcohol withdrawal syndrome, muscle spasms, insomnia, panic disorder, delirium, chemotherapy-associated anticipatory nausea and vomiting, and psychogenic catatonia.[T385]
Marketing Status approved
ATC Code N05BA06
DrugBank ID DB00186
KEGG ID D00365
MeSH ID D008140
PubChem ID 3958
TTD Drug ID D0E0OG
NDC Product Code 0641-6047; 0641-6049; 0904-6008; 71554-009; 72166-001; 0093-3426; 0121-0770; 52427-663; 55154-7976; 60687-638; 65162-018; 68788-7533; 69315-904; 70518-0275; 70518-0445; 0641-6002; 0641-6048; 72789-236; 76329-8261; 0904-6007; 51927-0195; 67763-101; 76420-296; 0093-3427; 52427-661; 61919-062; 63187-536; 67296-1478; 67296-1622; 68071-5022; 0409-6778; 71205-235; 71335-1467; 71610-600; 72572-380; 0641-6000; 0641-6001; 0641-6003; 0641-6051; 48087-0076; 51927-1005; 55154-7975; 61919-607; 67296-1332; 67544-142; 71610-008; 71610-654; 71610-655; 58118-1095; 63304-773; 65162-687; 68071-4916; 68071-5250; 70518-0486; 70518-2186; 70518-2442; 71205-228; 71335-0329; 71335-1455; 71335-1694; 0641-6207; 57218-950; 0187-0064; 53002-5291; 58118-0904; 60760-516; 63187-576; 68071-2666; 70934-782; 72789-197; 72789-226; 0904-6009; 13107-085; 0187-0065; 50383-705; 54348-049; 60687-627; 60687-649; 63304-774; 65162-015; 71335-1138; 71610-255; 12828-0025; 0093-3425; 53002-6290; 67544-191; 68071-3096; 0409-1985; 68788-7355; 70518-1275; 70518-3188; 70518-3423; 71205-166; 71205-756; 71610-122; 71610-229; 71610-674; 0641-6044; 0641-6046; 0641-6050; 64330-020; 43353-255; 52427-658; 55154-7977; 63304-772; 68788-7428; 69315-906; 70518-2268; 70518-3225; 72189-351; 17478-040; 52427-667; 55700-778; 65162-017; 67544-261; 70518-1520; 0054-3532; 71335-0655; 49452-4140; 51552-0729; 13107-083; 50090-5508; 63629-2953; 68071-2662; 68071-3121; 68071-5068; 69315-905; 71610-178; 71610-199; 71610-225; 0641-6045; 52696-0002; 62991-1682; 13107-084; 45865-499; 0187-0063; 50090-5509; 58118-1096
UNII O26FZP769L
Synonyms Lorazepam | Ativan | Orfidal Wyeth | Wyeth, Orfidal | Témesta | Tolid | Donix | Duralozam | Durazolam | Idalprem | Laubeel | Lorazep Von Ct | Von Ct, Lorazep | Lorazepam Medical | Medical, Lorazepam | Lorazepam-Neuraxpharm | Lorazepam Neuraxpharm | Lorazepam-Ratiopharm | Lorazepam Ratiopharm | Novo-Lorazem | Novo Lorazem | Nu-Loraz | Nu Loraz | Sedicepan | Sinestron | WY-4036 | WY 4036 | WY4036 | Apo-Lorazepam | Apo Lorazepam | Somagerol | Temesta
Chemical Information
Molecular Formula C15H10Cl2N2O2
CAS Registry Number 846-49-1
SMILES C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Withdrawal syndrome19.07.06.023; 08.06.02.0120.000453%Not Available
Mental status changes19.07.01.0010.000668%Not Available
Mobility decreased15.03.05.023; 17.02.05.018; 08.01.03.030--Not Available
Skin maceration23.03.03.0160.000046%Not Available
Hypoacusis04.02.01.0060.000046%
Performance status decreased08.01.03.0420.000046%Not Available
Paradoxical drug reaction08.06.01.0140.000222%Not Available
Peripheral swelling08.01.03.053; 02.05.04.015--Not Available
Brain oedema17.07.02.003; 12.01.10.0100.000092%
Weight fluctuation14.03.02.002--Not Available
Chapped lips07.05.01.004--Not Available
Psychomotor skills impaired19.22.01.002; 17.02.10.0050.000123%Not Available
General physical health deterioration08.01.03.0180.000185%Not Available
Left ventricular dysfunction02.04.02.0110.000031%
Muscle tightness15.05.03.0070.000083%Not Available
Balance disorder08.01.03.081; 17.02.02.0070.000296%Not Available
Bradyphrenia19.10.03.002; 17.03.03.0040.001109%Not Available
Dysstasia15.03.05.011; 08.01.03.089; 17.02.02.0120.000145%Not Available
Self-injurious ideation19.12.01.0070.000031%Not Available
Cytokine release syndrome10.02.01.0100.000031%
Metabolic syndrome14.06.02.007; 05.06.02.007; 24.08.02.0140.000077%Not Available
Gastrointestinal hypomotility07.02.02.0050.000031%Not Available
Ocular discomfort06.08.03.008--Not Available
Drug tolerance08.06.01.0030.000114%Not Available
Musculoskeletal stiffness15.03.05.027--Not Available
Alcohol withdrawal syndrome19.07.06.005; 08.06.02.0020.000062%Not Available
Inappropriate antidiuretic hormone secretion05.03.03.001; 14.05.07.0010.000154%Not Available
Injection site swelling12.07.03.018; 08.02.03.0170.000068%Not Available
Secretion discharge08.01.03.0190.000046%Not Available
Affect lability19.04.01.0010.000151%Not Available
The 13th Page    First    Pre   13 14 15 16 17    Next   Last    Total 17 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene